Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Stocks in play: Oncolytics Biotech Inc

Baystreet.ca - Baystreet - Fri Oct 4, 7:46AM CDT

Today issued a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025. Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval. Key milestones in gastrointestinal cancer clinical trials are expected in 2025, with potential for new registration-enabling studies. Oncolytics Biotech Inc shares T.ONC are trading up $0.07 at $1.27.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).